Bulletin From Extraordinary General Meeting in Senzime AB (publ)
Rhea-AI Summary
At Senzime AB's extraordinary general meeting on October 23, 2024, shareholders unanimously approved the board's resolution for a directed share issue originally decided on September 27, 2024. The issue comprises a maximum of 1,104,000 shares at a subscription price of SEK 6.20 per share, with subscription rights granted to Adam Dahlberg and Sorin J. Brull. This will increase the company's share capital by up to SEK 138,000. The subscription deadline is set for October 28, 2024, and payment must be made in cash.
Positive
- None.
Negative
- Share dilution through directed issue of 1,104,000 new shares
UPPSALA, SWEDEN / ACCESSWIRE / October 23, 2024 / The extraordinary general meeting in Senzime AB (STO:SEZI)(OTCQX:SNZZF) (publ), corp. reg. no 556565-5734 (the "Company") was held on 23 October 2024, whereby the shareholders primarily resolved on the following matter. All resolutions were unanimous.
Resolution on the approval of the board of directors' resolution on a directed share issue
In accordance with previously published information, the board of directors resolved 27 September 2024 on a directed issue of shares, subject to the subsequent approval of the extraordinary general meeting. The general meeting resolved today to approve the board of directors' resolution on a directed issue of a maximum of 1,104,000 shares. The right to subscribe for new shares shall, with deviation from the shareholders' pre-emption rights, belong to Adam Dahlberg and Sorin J. Brull.
The Company's share capital will increase by a maximum of SEK 138,000 through a directed issue of a maximum of 1,104,000 shares. The subscription price for the shares in the new issue is SEK 6.20 per share. Subscription shall be made by cash payment or on a subscription list not later than 28 October 2024.
For further information, please contact:
Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com
Slavoljub Grujicic, CFO
Phone: +46 (0) 76 306 60 11, e-mail: slavoljub.grujicic@senzime.com
About Senzime
Senzime develops CE- and FDA-cleared precision-based patient monitoring solutions to safeguard patients during anesthesia and recovery. Senzime's TetraGraph® and ExSpiron® 2Xi systems are powered by proprietary, smart algorithms to monitor neuromuscular and respiratory function in real-time during and after surgery. The technologies are based on 40+ years of science and developed to enhance patient safety targeting over 100 million patients globally. Senzime's products are commercialized in over 30 countries including direct sales teams in US and Germany.
Established in 1999 and headquartered in Uppsala, Sweden, Senzime is backed by long-term investors and listed on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the New York OTCQX market (SNZZF). More information is available at senzime.com.
Attachments
Bulletin from extraordinary general meeting in Senzime AB (publ)
SOURCE: Senzime
View the original press release on accesswire.com
FAQ
What is the subscription price for Senzime's (SNZZF) new share issue announced on October 23, 2024?
How many new shares will be issued in Senzime's (SNZZF) October 2024 directed share issue?
When is the subscription deadline for Senzime's (SNZZF) directed share issue announced in October 2024?
How much will Senzime's (SNZZF) share capital increase through the October 2024 directed share issue?
